Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mochida and Itochu to Each Take 20% Stake in And Pharma
Mochida Pharmaceutical and trader Itochu said on September 22 that they will each acquire a 20% stake in And Pharma, the holding company for Nichi-Iko Pharmaceutical, Kyowa Pharmaceutical Industry, and T’s Pharma. On October 1, the two firms will subscribe…
To read the full story
Related Article
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Mochida Sees Domestic Biosimilar Supply Gains in And Pharma Tie-Up
September 26, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
BUSINESS
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- Rege Nephro Raises 1.22 Billion Yen to Advance ADPKD Drug, iPSC Kidney Program
June 23, 2026
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…